FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:KMT2C-PDE8A

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: KMT2C-PDE8A
FusionPDB ID: 43257
FusionGDB2.0 ID: 43257
HgeneTgene
Gene symbol

KMT2C

PDE8A

Gene ID

58508

5151

Gene namelysine methyltransferase 2Cphosphodiesterase 8A
SynonymsHALR|KLEFS2|MLL3HsT19550
Cytomap

7q36.1

15q25.3

Type of geneprotein-codingprotein-coding
Descriptionhistone-lysine N-methyltransferase 2CALR-like proteinhistone-lysine N-methyltransferase MLL3histone-lysine N-methyltransferase, H3 lysine-4 specifichomologous to ALR proteinlysine (K)-specific methyltransferase 2Cmyeloid/lymphoid or mixed-lineage lehigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AcAMP-specific cyclic nucleotide phosphodiesterase 8A
Modification date2020032020200313
UniProtAcc

Q8NEZ4

Main function of 5'-partner protein: FUNCTION: Histone methyltransferase that methylates 'Lys-4' of histone H3 (PubMed:22266653). H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Central component of the MLL2/3 complex, a coactivator complex of nuclear receptors, involved in transcriptional coactivation. KMT2C/MLL3 may be a catalytic subunit of this complex. May be involved in leukemogenesis and developmental disorder. {ECO:0000269|PubMed:17500065, ECO:0000269|PubMed:22266653}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000262189, ENST00000355193, 
ENST00000485241, ENST00000485655, 
ENST00000339708, ENST00000394553, 
ENST00000557957, ENST00000557819, 
ENST00000310298, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score26 X 23 X 12=717610 X 10 X 4=400
# samples 3211
** MAII scorelog2(32/7176*10)=-4.4870360800319
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(11/400*10)=-1.86249647625006
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: KMT2C [Title/Abstract] AND PDE8A [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: KMT2C [Title/Abstract] AND PDE8A [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)KMT2C(151900019)-PDE8A(85607601), # samples:1
Anticipated loss of major functional domain due to fusion event.KMT2C-PDE8A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
KMT2C-PDE8A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
KMT2C-PDE8A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
KMT2C-PDE8A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneKMT2C

GO:0097692

histone H3-K4 monomethylation

26324722



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:151900019/chr15:85607601)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across KMT2C (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across PDE8A (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000262189KMT2Cchr7151900019-ENST00000310298PDE8Achr1585607601+7857431120766142135
ENST00000355193KMT2Cchr7151900019-ENST00000310298PDE8Achr1585607601+7857431120766142135

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000262189ENST00000310298KMT2Cchr7151900019-PDE8Achr1585607601+0.0005156020.9994844
ENST00000355193ENST00000310298KMT2Cchr7151900019-PDE8Achr1585607601+0.0005156020.9994844

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for KMT2C-PDE8A

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
KMT2Cchr7151900019PDE8Achr158560760143111366KRKNKLEETFPAYLQVAVADVQFGPM

Top

Potential FusionNeoAntigen Information of KMT2C-PDE8A in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
KMT2C-PDE8A_151900019_85607601.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B18:01EETFPAYL0.99780.9721614
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B56:01FPAYLQVA0.99050.6149917
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A66:01ETFPAYLQV0.99970.829716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A26:03ETFPAYLQV0.99870.8612716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A68:06ETFPAYLQV0.9980.7623716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B56:01FPAYLQVAV0.9950.6261918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:01FPAYLQVAV0.99470.7689918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:02FPAYLQVAV0.99460.7174918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:04FPAYLQVAV0.9920.949918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:02FPAYLQVAV0.9920.949918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A26:02ETFPAYLQV0.98840.8616716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:11YLQVAVADV0.98490.53421221
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:03FPAYLQVAV0.98320.7885918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A26:15ETFPAYLQV0.98040.8959716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A26:14ETFPAYLQV0.98040.8959716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:27YLQVAVADV0.97850.52141221
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:01FPAYLQVAV0.97280.7871918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A34:01ETFPAYLQV0.96650.7039716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A34:05ETFPAYLQV0.96650.7039716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:08FPAYLQVAV0.96520.7443918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:05FPAYLQVAV0.9570.7005918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B39:06FPAYLQVAV0.9570.9856918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:02ETFPAYLQV0.93460.7529716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B53:01FPAYLQVAV0.91490.5186918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B08:09FPAYLQVAV0.85780.8054918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:01ETFPAYLQV0.78810.9062716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:21ETFPAYLQV0.77160.804716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A66:03ETFPAYLQV0.75220.5522716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B52:01ETFPAYLQV0.6980.9942716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B82:01FPAYLQVAV0.58740.5764918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B81:01FPAYLQVAV0.55470.5586918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B39:13LEETFPAYL0.38240.9741514
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:67KLEETFPAYL0.99260.86414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:30KLEETFPAYL0.99260.86414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:60KLEETFPAYL0.99260.8484414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:24KLEETFPAYL0.99260.86414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:11KLEETFPAYL0.99240.8754414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B56:01FPAYLQVAVA0.99120.6481919
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A68:06ETFPAYLQVA0.99060.848717
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:22KLEETFPAYL0.98960.8151414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:04KLEETFPAYL0.98920.7646414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:16KLEETFPAYL0.98780.7509414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:17KLEETFPAYL0.9870.624414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:27KLEETFPAYL0.98610.7575414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:13KLEETFPAYL0.98410.8275414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:38KLEETFPAYL0.97530.7871414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:19KLEETFPAYL0.93410.591414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:29KLEETFPAYL0.86990.8587414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:35KLEETFPAYL0.86590.8723414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:20KLEETFPAYL0.84280.8653414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A68:06EETFPAYLQV0.80.6878616
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A68:06ETFPAYLQVAV0.99830.9171718
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B54:01FPAYLQVA0.99750.8839917
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B78:01FPAYLQVA0.99080.9109917
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B54:01FPAYLQVAV0.99870.8815918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B78:01FPAYLQVAV0.9970.926918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-C15:06ETFPAYLQV0.99540.9475716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:07FPAYLQVAV0.99470.8467918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:12FPAYLQVAV0.9920.949918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-C15:04ETFPAYLQV0.99140.9424716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B44:10LEETFPAYL0.98610.6195514
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B56:04FPAYLQVAV0.98230.8018918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A26:01ETFPAYLQV0.98040.8959716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:08FPAYLQVAV0.96450.6616918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B42:02FPAYLQVAV0.95070.7315918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B42:01FPAYLQVAV0.92050.7314918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B78:01ETFPAYLQV0.85140.9548716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-C12:04ETFPAYLQV0.84490.9978716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-C06:03ETFPAYLQV0.82970.9978716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:05ETFPAYLQV0.82540.7174716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:08ETFPAYLQV0.81920.8177716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B39:10FPAYLQVAV0.81120.9701918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-C02:06ETFPAYLQV0.77240.9869716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:07ETFPAYLQV0.73760.9912716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B39:08LEETFPAYL0.53210.9373514
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B54:01FPAYLQVAVA0.99860.8775919
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:07KLEETFPAYL0.99330.8583414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:01KLEETFPAYL0.99260.86414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:02KLEETFPAYL0.99080.5294414
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B78:01FPAYLQVAVA0.93320.9072919
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B18:05EETFPAYL0.99780.9721614
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B18:03EETFPAYL0.99660.9702614
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B18:06EETFPAYL0.99660.9773614
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B78:02FPAYLQVA0.99620.973917
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B56:05FPAYLQVA0.99490.8139917
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B55:02FPAYLQVA0.98780.7711917
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A68:02ETFPAYLQV0.99960.8357716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A69:01ETFPAYLQV0.9990.8705716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B40:04LEETFPAYL0.99840.7689514
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:22FPAYLQVAV0.99740.6504918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B78:02FPAYLQVAV0.99690.9674918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-C15:02ETFPAYLQV0.9960.9575716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-C15:05ETFPAYLQV0.99580.9754716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:14FPAYLQVAV0.99510.7099918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:09FPAYLQVAV0.99510.8375918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B56:05FPAYLQVAV0.99440.781918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:13FPAYLQVAV0.99410.7258918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:21FPAYLQVAV0.99350.7592918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:06FPAYLQVAV0.99260.7657918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:09FPAYLQVAV0.9920.949918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A25:01ETFPAYLQV0.99190.9489716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B55:02FPAYLQVAV0.99170.77918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-C15:09ETFPAYLQV0.99140.9424716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B59:01FPAYLQVAV0.98740.8268918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B55:04FPAYLQVAV0.98540.7976918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:13FPAYLQVAV0.9830.7899918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B56:02FPAYLQVAV0.98230.8018918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:23FPAYLQVAV0.97680.7916918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:77FPAYLQVAV0.97280.7871918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:29FPAYLQVAV0.94920.5662918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:17FPAYLQVAV0.94830.7455918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:30FPAYLQVAV0.94830.7455918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A69:01FPAYLQVAV0.93510.7885918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A66:02ETFPAYLQV0.93040.5442716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:24FPAYLQVAV0.92080.7789918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B67:01FPAYLQVAV0.90110.9632918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:21ETFPAYLQV0.87930.8513716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:11FPAYLQVAV0.8790.8213918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-C16:04ETFPAYLQV0.86890.9933716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:05FPAYLQVAV0.86180.5336918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B53:02FPAYLQVAV0.84820.6502918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B59:01ETFPAYLQV0.81960.8669716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B07:26FPAYLQVAV0.78780.5078918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:14ETFPAYLQV0.77430.8417716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:13ETFPAYLQV0.77230.8375716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A02:06ETFPAYLQV0.77160.804716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B51:09ETFPAYLQV0.76440.856716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-C12:03ETFPAYLQV0.64070.9935716
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B82:02FPAYLQVAV0.58740.5764918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B39:02LEETFPAYL0.4110.9761514
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B41:03LEETFPAYL0.32450.7148514
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B18:07FPAYLQVAV0.25130.7367918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B35:43FPAYLQVAV0.0340.8404918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B15:08FPAYLQVAV0.0280.8384918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B15:11FPAYLQVAV0.0260.8495918
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A68:02ETFPAYLQVA0.99490.8129717
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A69:01ETFPAYLQVA0.99030.8187717
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B55:02FPAYLQVAVA0.98770.7837919
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B56:05FPAYLQVAVA0.970.7821919
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A68:02EETFPAYLQV0.91560.8724616
KMT2C-PDE8Achr7151900019chr15856076014311HLA-B78:02FPAYLQVAVA0.89160.964919
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A69:01EETFPAYLQV0.86960.8797616
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A68:02ETFPAYLQVAV0.99970.8246718
KMT2C-PDE8Achr7151900019chr15856076014311HLA-A69:01ETFPAYLQVAV0.99910.848718

Top

Potential FusionNeoAntigen Information of KMT2C-PDE8A in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
KMT2C-PDE8A_151900019_85607601.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
KMT2C-PDE8Achr7151900019chr15856076014311DRB4-0101PAYLQVAVADVQFGP1025
KMT2C-PDE8Achr7151900019chr15856076014311DRB4-0103PAYLQVAVADVQFGP1025
KMT2C-PDE8Achr7151900019chr15856076014311DRB4-0104PAYLQVAVADVQFGP1025
KMT2C-PDE8Achr7151900019chr15856076014311DRB4-0106PAYLQVAVADVQFGP1025
KMT2C-PDE8Achr7151900019chr15856076014311DRB4-0107PAYLQVAVADVQFGP1025
KMT2C-PDE8Achr7151900019chr15856076014311DRB4-0108PAYLQVAVADVQFGP1025

Top

Fusion breakpoint peptide structures of KMT2C-PDE8A

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
1700EETFPAYLQVAVADKMT2CPDE8Achr7151900019chr15856076014311

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of KMT2C-PDE8A

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN1700EETFPAYLQVAVAD-8.89215-9.00555
HLA-B14:023BVN1700EETFPAYLQVAVAD-7.28258-8.31788
HLA-B52:013W391700EETFPAYLQVAVAD-6.74581-6.85921
HLA-B52:013W391700EETFPAYLQVAVAD-5.83942-6.87472
HLA-A11:014UQ21700EETFPAYLQVAVAD-11.5751-11.6885
HLA-A11:014UQ21700EETFPAYLQVAVAD-7.74694-8.78224
HLA-A24:025HGA1700EETFPAYLQVAVAD-8.95896-9.07236
HLA-A24:025HGA1700EETFPAYLQVAVAD-4.62044-5.65574
HLA-B44:053DX81700EETFPAYLQVAVAD-7.69132-7.80472
HLA-B44:053DX81700EETFPAYLQVAVAD-6.01568-7.05098
HLA-A02:016TDR1700EETFPAYLQVAVAD-4.90042-5.01382

Top

Vaccine Design for the FusionNeoAntigens of KMT2C-PDE8A

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
KMT2C-PDE8Achr7151900019chr15856076011221YLQVAVADVCAAGTAGCAGTAGCTGATGTGCAGTTT
KMT2C-PDE8Achr7151900019chr1585607601414KLEETFPAYLGAAGAAACTTTCCCTGCCTATTTACAAGTA
KMT2C-PDE8Achr7151900019chr1585607601514LEETFPAYLGAAACTTTCCCTGCCTATTTACAAGTA
KMT2C-PDE8Achr7151900019chr1585607601614EETFPAYLACTTTCCCTGCCTATTTACAAGTA
KMT2C-PDE8Achr7151900019chr1585607601616EETFPAYLQVACTTTCCCTGCCTATTTACAAGTAGCAGTA
KMT2C-PDE8Achr7151900019chr1585607601716ETFPAYLQVTTCCCTGCCTATTTACAAGTAGCAGTA
KMT2C-PDE8Achr7151900019chr1585607601717ETFPAYLQVATTCCCTGCCTATTTACAAGTAGCAGTAGCT
KMT2C-PDE8Achr7151900019chr1585607601718ETFPAYLQVAVTTCCCTGCCTATTTACAAGTAGCAGTAGCTGAT
KMT2C-PDE8Achr7151900019chr1585607601917FPAYLQVAGCCTATTTACAAGTAGCAGTAGCT
KMT2C-PDE8Achr7151900019chr1585607601918FPAYLQVAVGCCTATTTACAAGTAGCAGTAGCTGAT
KMT2C-PDE8Achr7151900019chr1585607601919FPAYLQVAVAGCCTATTTACAAGTAGCAGTAGCTGATGTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
KMT2C-PDE8Achr7151900019chr15856076011025PAYLQVAVADVQFGPTATTTACAAGTAGCAGTAGCTGATGTGCAGTTTGGCCCCATGAGA

Top

Information of the samples that have these potential fusion neoantigens of KMT2C-PDE8A

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADKMT2C-PDE8Achr7151900019ENST00000262189chr1585607601ENST00000310298TCGA-HU-A4GN-01A

Top

Potential target of CAR-T therapy development for KMT2C-PDE8A

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to KMT2C-PDE8A

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to KMT2C-PDE8A

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource